SRE Platform Engineer, Aqemia
3+ days a week in office
AI and quantum physics driven drug discovery
Be an early applicant
AI and quantum physics driven drug discovery
21-100 employees
Be an early applicant
3+ days a week in office
21-100 employees
Company mission
To design fast innovative drug candidates for dozens of critical diseases, such as immuno-oncology.
Role
Who you are
- 4+ years of experience in DevOps, platform engineering, or infrastructure automation
- Strong experience with CI/CD tools (e.g. Github Actions, ArgoCD)
- Proficiency in scripting (Python, Bash) and infrastructure-as-code (Terraform, Terragrunt…)
- Deep familiarity with Docker, Kubernetes, and cloud platforms (AWS preferred)
- Solid understanding of deployment strategies, secrets management, and system monitoring
- Ability to work autonomously and collaborate across diverse technical teams
Desirable
- You believe great DevOps = speed + reliability + simplicity
- You love making other engineers’ lives easier
- You care about clean automation and reducing manual overhead
- You enjoy working behind the scenes to support high-impact science
What the job involves
- As an SRE - Platform Engineer in the Infra Team, you will be at the heart of our platform, helping to build and maintain the tools, processes, and systems that power Aqemia's drug discovery engine
- You will contribute to the design and implementation of a scalable and resilient infrastructure, focusing on both enhancing the developer experience and ensuring the reliability, performance, and availability of our services
- Your work is crucial for enabling our scientists, engineers, and AI models to develop, test, and deploy their work efficiently and without interruption
- In this key, cross-functional role, you will collaborate with multiple teams to improve our core infrastructure and promote engineering best practices
- Design, implement, and maintain systems to ensure platform uptime, performance, and scalability
- Automate infrastructure provisioning and configuration with infrastructure-as-code tools
- Optimize build/test/deploy workflows for performance, reliability, and developer usability
- Participate to the technical roadmap definition with the team
- Define and improve SLOs, SLAs, monitoring, alerting, and incident response processes
- Collaborate with product stakeholders and engineering teams to build resilient, observable systems
- Manage containerized environments and orchestrators (Kubernetes) across multiple projects
- Participate to cross-functional discussions and translate business needs into infra priorities
- Ensure infrastructure security, scalability, and cost-efficiency
- Monitor and continuously improve system performance and deployment processes
Our take
The billion dollar drug discovery industry is set to see notable growth by 2032 with huge R&D investments being made. It’s generally accepted that this is one of the most important financed sectors in the world. AQEMIA joined the discovery train in 2019 with its deep physics and AI enabled drug revelation pipeline.
The company boasts its intricate level of accuracy within its physics algorithms that are fed into AI discovery, leading to a level of speed and in turn scaling drug discovery at an impressive rate. Creating a name for itself AQEMIA moves away from using experimental data and bases the AI powered outcomes on years of data and studies of its now impressive team of 50.
Aqemia’s discoveries have already made an impact in oncology and immuno-oncology trials. The company sets goals to be part of more life changing clinical trials with wholly or partly owned drug candidates and with significant funding continues to scale its platform to continue wins in its research. It will be exciting to see how more research and collaborations like that with Servier (international pharmaceutical company) will continue to grow its success.
Steph
Company Specialist at Welcome to the Jungle
Company
Funding (last 2 of 6 rounds)
Apr 2025
$7.4m
GRANT
Dec 2024
$42.1m
EARLY VC
Total funding: $131.7m
Company HQ
Necker, Paris, France
Leadership
Maximilien Levesque
(Co-Founder & CEO)Currently a Board Member of France Biotech. Founded Personal HPC and worked through several roles at École normale supérieure most recently as a Research Group Leader.
Emmanuelle Martiano Rolland
(Co-Founder & COO)Previous Principal at Boston Consulting Group after completing a Master of Science Imperial College of London.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job
View 5 more jobs at Aqemia